(RTTNews) - Johnson & Johnson (JNJ) reported three-year data showing sustained clinical and endoscopic remission with Tremfya (guselkumab) in adults with moderately to severely active Crohn's disease.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.